Renal Endocrinology Moderate — endorsed by KDIGO CKD-MBD guidelines
Calcium-Phosphate Product
Calculates the calcium-phosphate product to assess risk of metastatic calcification in chronic kidney disease (CKD), particularly vascular and soft tissue calcification.
References
- Block GA, et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15(8):2208–2218.
- KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of CKD-MBD.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
Drugs
- Ergocalciferol with calcium lactate and calcium phosphate · Combined calcium + vitamin D
- Calcium phosphate · Calcium phosphate supplement
- Calcium Acetate 667mg (PhosEx) · Phosphate Binder (Calcium-Based)
- Lanthanum Carbonate · Phosphate Binder (Non-Calcium-Based)
- Calcium acetate · Phosphate binder (calcium-based)
- Calcium acetate with magnesium carbonate · Combination phosphate binder
Pathways
- Hyperkalaemia Management · UK Kidney Association Guidelines 2020; NICE CKD Guidelines
- Acute Kidney Injury (AKI) · KDIGO 2012 / NICE AKI 2019
- CKD Management · NICE CKD 2021 / KDIGO 2024
- Nephrotic Syndrome · KDIGO 2021
- RRT Initiation · KDIGO 2012 / NICE
- Diabetic Ketoacidosis (DKA) · JBDS 2013 / Joint British Diabetes Societies; NICE NG17
Decision support only — verify against MDCalc, NICE, or your local guideline before clinical use.